NCT02779634

Ubiquinol Treatment in Patients With Heart Failure and Preserved Ejection Fraction

The Effect of Ubiquinol Treatment on Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Hadassah Medical Organization · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

There are no studies specifically examining the effects of coenzyme Q (CoQ) treatment on echocardiographic indices of diastolic function in elderly patients with heart failure with preserved ejection fraction (HFPEF). In previous studies the only echocardiographic parameters studied were ejection fraction (EF) and chamber size. The objective of the proposed current study is to examine the effect of 16 weeks of ubiquinol therapy on diastolic function assessed by echocardiography in patients over the age of 50 with a clinical diagnosis of HFPEF. Ubiquinol (Kaneka Pharma), the reduced form of CoQ will be utilized for this study as it has been shown to have superior bioavailability when compared to oxidized CoQ.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	ubiquinol	Ubiquinol three times daily
DRUG	Placebo	Sugar pill three times daily

Timeline

• Start date: 2016-07-01
• Primary completion: 2018-01-01
• Completion: 2018-01-01
• First posted: 2016-05-20
• Last updated: 2016-05-20